

MS ASCEND UCITS FUND

A SUB-FUND OF FUNDLOGIC ALTERNATIVES PLC, AN IRISH UCITS FUND

FUND OBJECTIVE AND INVESTMENT STRATEGY

The Ascend Investment Strategy is an opportunistic U.S.- focused Long/ Short equity investment strategy.

The strategy is a variation of the "Jones Model" investing strategy with the intention of achieving capital appreciation in a broad range of market environments. The Jones Model is an investment strategy whereby the portfolio is long securities and short securities, and which seeks to hedge against market fluctuations. The strategy is focused on targeting absolute returns rather than returns that are correlated to the broad stock market. The Investment Manager invests in companies it identifies through a disciplined process involving thorough bottom-up fundamental research.

The sub-fund provides shareholders with a return linked to the performance of the Ascend Investment Strategy through the use of total return swaps.

INVESTMENT MANAGER

Established in 1999, Ascend Capital LLC is a Delaware limited liability company registered as an investment adviser with the U.S. Securities and Exchange Commission. The company was founded by Malcolm Fairbairn who has 20 years experience as a Long/Short portfolio manager, delivering positive net returns in 18 of the 20 years.

Ascend Capital LLC manages approximately \$3.2 billion of assets under management and has 23 investment professionals: 1 Chief Investment Officer, 6 Portfolio Managers, 3 Sector Managers, 9 Researchers, 1 Director of Analytics and 3 Traders, and is headquartered in Orinda with a satellite office in San Francisco.

HISTORICAL MONTHLY RETURNS

	65% -0.889	% -0.61%	-0.34%	-7.06%
			010170	7.0070
2012 0.42% 0.46% -0.37% 1.20% 0.29% -0.29% -0.61% 0.48% 0.0	0.929	% -0.60%	-0.21%	-0.14%
2013 2.42% 0.33% 1.27% -0.58% 0.45% -0.10% 0.88% -0.01% 1.6	53% 1.86%	6 1.73%	1.70%	12.16%
2014 0.00% 2.06% 0.11% -2.06% 1.35% 1.21% 0.59% -0.07% 0.9	96% -0.029	%		4.15%

INVESTMENT MANAGER COMMENTARY²

Significant market volatility in October made for a challenging environment. On October 15, the S&P 500 was down over 5%, on weakening global economy fears, falling 10-year US Treasury bond rates and the potential threat of Ebola spreading in the US. However, these concerns were shortlived as the market rallied through the end of the month, with the S&P 500 increasing over 2% and the Russell 2000 Index was up over 6%. The HFRI Index was up 0.31% for the month. The MS Ascend UCITS Fund was down -0.02%.

In the portfolio, the major contributor to performance was from stocks in the Tech sector. The Tech portfolio contributed over 150 basis points to performance, with positive performance on both the long and shorts. The Technology sector slightly underperformed the broader market in October as earnings season revealed a slowing of enterprise IT spending as well as more meaningful downward adjustments to rates of capital spending across the telecommunications complex. The most profitable longs were in companies with stronger than expected Q3 earnings that reached our price target for the year. The most profitable short positions were Japanese consumer electronics and companies with disappointing Q3 earnings. Materials and Consumer Discretionary sectors were also contributors to performance in October, while

sed on unaudited figures. * For 2011, May and YTD performances start from May 20th, 2011.

Healthcare and Industrials were the largest detractors. Materials had a solid month in October driven primarily by packaging names. In addition to packaging names, we remain constructive on those names tethered to lower commodity prices, namely protein processors and other agriculturally tethered names. In the Consumer Discretionary sector, the main drivers of performance were power sports, cruise lines and cable names. We continue to be constructive on select media/cable stocks as well as power sports and motorcycles, while negative on lodging stocks at these valuations.

The Healthcare portfolio suffered losses on both the longs and shorts. In addition to company specific events, the termination of the AbbVie and Shire deal caused a short squeeze across many names within Healthcare. In the Industrials portfolio, losses were related to companies in the aerospace sector and companies with oil exposure.

We maintain our view that it is a good environment for stock picking. The fundamental backdrop in US is still very positive and this is a good environment for creating alpha on the longs and shorts.

¹ Index information is included for illustration purposes only and is not intended to imply that the portfolio was similar to any index either in composition or element of risk.

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundLogic Alternatives pic (the "Fund") should not be made without first consulting the Fund's current prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.

FUND CHARACTERISTICS

	_				
Inception Date	13th May, 2011				
Total Assets (USD)	\$ 170 Million				
Base Currency	USD				
Domicile	Ireland				
Passporting Status (registered in)	UK, Spain, Italy, Germany, France				
Legal Structure	An Open-Ended Investment Company (OEIC)				
	Weekly. Every Friday (except legal public				
Dealine Dev	holidays in the UK, Ireland or US and days on				
Dealing Day	which stock markets in London or New York are				
	closed)				
Subscription/Dedemption notice	12 midday Irish time, 3 business days prior to the				
Subscription/ Redemption notice	relevant dealing day				
Settlement	Subscription: Dealing Day +3				
Settlement	Redemption: Dealing Day +5				
Currency Classes Available	EUR / USD / GBP				
Investment Manager	Ascend Capital LLC				
Promoter & Distributor	Morgan Stanley & Co International plc				
Custodian	Northern Trust Fiduciary Services (Ireland) Ltd				
Administrator	Northern Trust International Fund Administration				
Auministrator	Services (Ireland) Ltd				
Auditor	Ernst & Young				

PERFORMANCE¹





Morgan Stanley

Factsheet - October 31st, 2014

FIGURES BELOW REPRESENT EXPOSURE TO THE ASCEND INVESTMENT STRATEGY

TOP HOLDINGS ³

TOP 5 LONGS					
COMPANY / SECTOR	% of NAV				
CROWN HOLDINGS INC	3.70%				
MICROSOFT CORP	2.96%				
PFIZER INC	2.63%				
BERRY PLASTICS GROUP	2.45%				
METHANEX CORP	2.29%				
	14.03%				


RISK METRICS⁴


EXPOSURE AND RISK SUMMARY					
	% of NAV				
Long Exposure	97%				
Short Exposure	-82%				
Gross Exposure	179%				
Net Exposure	15%				
Annualised Volatility ⁶	4.59%				
Relative VaR ⁷	0.27				

	Number of Positions
No. of Longs	188
No. of Shorts	170

Source: Morgan Stanley


SECTOR ANALYSIS⁴





Source: Morgan Stanley





Source: Morgan Stanley

³ Month-end data used. Exposures are delta adjusted, exclude market hedges

⁴ Month-end data used. Exposures are delta adjusted, include market hedges.

 $^{\rm 5}\,{\rm Per}$ country of issue of the underlying.

⁶ Indicative values as insufficient data points for statistical calculations. The volatility is computed as the standard deviation of the daily returns.

 7 Var 99% - 20 days computed against the S&P 500 as benchmark.

⁸ Mega Cap (>= 20 billion); Large Cap (>= 5 billion, < 20 billion); Mid Cap (>= 1 billion , < 5 billion); Small Cap (> 0, < 1 billion) .

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundLogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.



FUND SHARE CLASS DETAILS

Share Class			Performance			Identifiers			Fees				
	Ссу	Min Inv	Launch Date	NAV	MTD	YTD	LTD	ISIN	BBG	SEDOL	Mgmt	Perf.	TER ⁹
Class I	EUR	1,000,000	20/05/2011	1,084.16	-0.02%	4.15%	8.42%	IE00B53HHV28	FLMSAIE ID	B53HHV2	1.5%	20%	1.92%
Class P	USD	250,000	09/09/2011	1,138.15	-0.05%	4.05%	13.82%	IE00B53STN13	FLMSAPU ID	B53STN1	1.5%	20%	1.92%
Class P	EUR	250,000	28/10/2011	1,152.44	-0.02%	4.14%	15.24%	IE00B4QLVM32	FLMSAPE ID	B4QLVM3	1.5%	20%	1.92%
Class S*	EUR	50,000,000	10/01/2014	1,036.84	0.00%	3.68%	3.68%	IE00BH5MGZ61	FLMSASE ID	BH5MGZ6	1.6%	20%	2.00%
Class I*	USD	1,000,000	29/08/2014	1,008.73	-0.05%	0.87%	0.87%	IE00B4XD6J42	FLMSAIU ID	B4XD6J4	1.5%	20%	1.90%

Total Expense Ratio includes Management Fees and Promoter Fees. For share classes launched before 31 July 2013, the TER is based on the expenses for the year ending 31 July 2013. This figure may vary from year to year

Source: Morgan Stanley. NAV are computed by Northern Trust

* The YTD 2014 return for the S EUR share class starts from 10th of January 2014 and for the I USD share class - from 29th of August 2014.

The Net Asset Value of FundLogic – MS Ascend UCITS is calculated daily and is posted on Bloomberg shortly thereafter. Additional profile information, including the investor transparency report, and estimated performance in the preceding week, is also available to be sent to Shareholders on request on a weekly basis. To request such information please contact Benjamin D. Slavet at ben@ascendcapital.com.

IMPORTANT INFORMATION

This document has been prepared by Morgan Stanley & Co International plc as a marketing document to inform Professional Investors and Eligible Counterparts about certain matters concerning the Fund. It has been prepared solely for informational purposes and does not seek to make any recommendation to buy or sell any particular security (including Shares in the Fund) or to adopt any specific investment strategy. Any use of this document by a financial intermediary is restricted to clients for whom the information in this document and an investment in Shares of the Fund has been considered to be suitable by that financial intermediary in view of that client's situation and purpose, subject always to the applicable regulatory standard. If such a client considers an investment in Shares of the Fund, she/he has been properly advised by that financial intermediary about the suitability of an investment.

This financial promotion has been issued and approved in the UK by Morgan Stanley & Co International plc, 25 Cabot Square, Canary Wharf, London E14 4QA, authorized and regulated by the Financial Conduct Authority, for distribution to Professional Clients or Eligible Counterparties only and must not be relied upon or acted upon by Retail Clients (each as defined in the UK Financial Conduct Authority's rules). All of the information contained in this document relating to Ascend Capital LLC (the "Ascend Information") is communicated by Ascend Capital LLC located at 4 Orinda Way Suite 200-C, Orinda, CA 94563, authorized and regulated by the Financial Conduct Authority. While the board of the Fund has overall responsibility for monitoring of the investment objective, policy and performance of the Fund, Morgan Stanley & Co International plc disclaims any and all liability relating to the Ascend Information, including, without limitation, any express or implied representations or warranties for statements or errors contained in, and omissions from, the Ascend Information.

This communication is a marketing communication; it has been prepared solely for information purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. Applications for shares in any sub-fund of the FundLogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, Key Investor Information Document, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge at the address above. The Offering Documents contain material information not contained herein. In particular, the Prospectus contains details relating to the terms of investment and information regarding investment risks and conflicts of interest. Any representation to the contrary is not permitted. In the event of such offering, the information in this document will be superseded, amended and/or supplemented in its entirety by the Prospectus. You should not rely solely on the information contained herein, including but not limited to the Ascend Information, but should carefully read, the Offering Documents before making any investment decision.

The material contained herein has not been based on a consideration of any individual client circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision. Except as otherwise indicated herein, the views and opinions expressed herein are those of Morgan Stanley & Co International plc. It is not a product of Morgan Stanley's Research Department and should not be regarded as a research recommendation. The information contained herein has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

No representation or warranty can be given with respect to the accuracy or completeness of the information, or with respect to the terms of any future offer of transactions conforming to the terms hereof. We do not undertake to update this information. Certain assumptions may have been made in the analysis that resulted in any information and returns/results detailed herein. No representation is made that any results/returns indicated would be achieved or that all assumptions in achieving these returns have been considered or stated. Changes to the assumptions may have a material impact on any results/returns detailed. Morgan Stanley and its affiliates disclaim any and all liability relating to this information, including without limitation any express or implied representations or warranties for statements contained in, and omissions from, this information. Additional information concerning the portfolio may be available upon request from the investment manager.

Although this report has been prepared using sources, models and data that Morgan Stanley ("MS") believes to be reasonably reliable, its accuracy, completeness or suitability cannot be guaranteed. Therefore, this information is supplied on an "AS IS" basis, and NO WARRANTY IS MADE AS TO ITS ACCURACY, COMPLETENESS, NON-INFRINGEMENT OF THIRD PARTY RIGHTS, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

Any index referred to herein is the intellectual property (including registered trademarks) of the applicable licensor. Any product based on an index is in no way sponsored, endorsed, sold or promoted by the applicable licensor and it shall not have any liability with respect thereto. All information contained herein is proprietary and is protected under copyright law.

The investment manager to the Fund may from time to time, at its sole discretion and out of its own resources, decide to rebate to Shareholders part or all of its investment management fee and/or performance fee. Any such rebates may be applied by issuing additional shares to shareholders or in cash. In addition to the information disclosed in the periodic reports of FundLogic Alternatives plc (the "Company"), the Company may, from time to time, make available to investors portfolio holdings and portfolio-related information in respect of one or more of the sub-funds including the Fund. Any such information will be available to all investors in the relevant sub-fund on request. Any such information will only be provided on a historical basis and after the relevant dealing day to which the information relates

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundLogic Alternatives pic (the "Fund") should not be made without first consulting the Fund's current Prospectus, KID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.



RISK WARNING:

Past performance is not a guarantee of future performance. The value of the investments and the income from them can go down as well as up and an investor may not get back the amount invested. There can be no assurance that the Fund will achieve its investment objectives.

Investments may be in a variety of currencies and therefore changes in rates of exchange between currencies may cause the value of investments to decrease or increase. Furthermore, the value of investments may be adversely affected by fluctuations in exchange rates between the investor's reference currency and the base currency of the investments.

Investments in derivative instruments carry certain inherent risks such as the risk of counter party default and before investing you should ensure you fully understand these risks. Use of leverage may also magnify losses as well as gains to the extent that leverage is employed.

These investments are designed for investors who understand and are willing to accept these risks. Performance may be volatile, and an investor could lose all or a substantial portion of his or her investment.

SELLING RESTRICTIONS:

The Fund may only be offered and distributed to investors in accordance with all relevant local laws and regulations. The distribution of this presentation and the offering or purchase of interests in the Fund may be restricted in certain countries. This communication is only intended for and will be only distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations. It is the responsibility of any persons in possession of this document and any persons wishing to purchase interests in the Fund to inform themselves of, and to observe, all applicable laws and regulations of any relevant country.

For Investors in Germany: The shares in the Fund are not registered or authorised for public distribution under the InvG. No Prospectus under the WpPG respectively the VPG has been published. Accordingly, the shares in the Fund must not be distributed within Germany by way of a public offer, public advertisement or in any similar manner and this and any other document relating to the shares in the Fund, as well as information contained therein, may not be supplied to the public in Germany or used in connection with any offer for subscription of shares to the public in Germany. This document as well as other offering materials relating to the offer of shares are strictly confidential and may not be distributed to any person or entity other than the recipients hereof.

For Investors in Hong Kong: This document is issued by Morgan Stanley Asia Limited ("Morgan Stanley") and has not been reviewed by the Securities and Futures Commission of Hong Kong. This document is only intended for and will only be distributed to persons that are professional investors as defined under the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong) and its subsidiary legislation as amended from time to time ("Professional Investors") and may not be circulated to the general public in Hong Kong. This Fund has not been authorised by the Securities and Futures Commission and may only be sold to Professional Investors. Applications for shares in the MS ASCEND UCITS Fund should not be made without first consulting the current Prospectus, Key Investor Information Document, Annual Report and Semi-Annual Report ("Offering Documents") of the Fund.

This document has been prepared as information for Professional Investors in Hong Kong and it is not a recommendation to buy or sell any particular security or to adopt any investment strategy. Investors should exercise caution and seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision. Except as otherwise indicated herein, the views and opinions expressed herein are those of Morgan Stanley, and are based on matters as they exist as of the date of preparation and not as of any future date, and will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date hereof. No representation or warranty is given with respect to the accuracy or completeness of the information herein. This document is not a product of Morgan Stanley's Research Department and should not be regarded as a research recommendation

For Investors in Singapore: This material is being disseminated in Singapore by Morgan Stanley Asia (Singapore) Pte. The Fund is not authorised or recognised by the Monetary Authority of Singapore ("Authority") and shares in the Funds ("Shares") are not allowed to be offered to the Singapore retail public. This material which relates to the offer of Shares in the Funds is not a prospectus as defined in the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and accordingly, statutory liability under the SFA in relation to the content of prospectuses would not apply. You should consider carefully whether the investment is suitable for you.

This material has not been registered as a prospectus by the Authority, and the offer of the Shares is made pursuant to the exemptions under Sections 304 and 305 of the SFA. Accordingly, the Shares may not be offered or sold, nor may the Shares be the subject of an invitation for subscription or purchase, nor may this material or any other document or material in connection with the offer or sale, or invitation for subscription or purchase of the Shares be circulated or distributed, whether directly or indirectly, to any person in Singapore other than under exemptions provided in the SFA for offers made (a) to an institutional investor (as defined in Section 4A of the SFA) pursuant to Section 304 of the SFA, (b) to a relevant person (as defined in Section 305(5) of the SFA), or any person pursuant to an offer referred to in Section 305(2) of the SFA, and in accordance with the conditions specified in Section 305 of the SFA or (c) otherwise pursuant to, and in accordance with, the conditions of any other applicable provision of the SFA.

Where the Shares are acquired by persons who are relevant persons specified in Section 305A of the SFA, namely:

(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,

the shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within 6 months after that corporation or that trust has acquired the Shares pursuant to an offer made under Section 305 of the SFA except:

(1) to an institutional investor or to a relevant person as defined in Section 305(5) of the SFA, or which arises from an offer referred to in Section 275(1A) of the SFA (in the case of that corporation) or which arises from an offer that is made on terms that such rights or interest in that trust are acquired at a consideration of not less than S\$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets (in the case of that trust);

(2) where no consideration is or will be given for the transfer; or

(3) where the transfer is by operation of law.

Any offering of the Shares in Singapore would be through Morgan Stanley Asia (Singapore) Pte., an entity regulated by the Authority.

For Investors in Australia: This document is not an offer document under Chapter 6D of the Australian Corporations Act 2001, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of an offer document under Chapter 6D of the Corporations Act. Accordingly: (i) the offer of shares under this document is only being made in Australia to "Sophisticated Investors" within the meaning of Section 708(8) of the Corporations Act or "Professional Investors" within the meaning of Section 708(11) of the Australian Corporations Act, in each case who are "wholesale clients" for the purposes of section 761G(7) of the Corporations Act; (ii) this document is being made available in Australia only to such persons; and (iii) each applicant for shares in Australia represents that the applicant is such a person and, unless permitted under the Corporations Act, agrees not to sell or offer for sale within Australia any of the shares issued to the applicant within 12 months after their issue to the applicant under this document. Offers and issues of shares under this document in Australia are being made pursuant to an arrangement with Morgan Stanley Australia Limited.

For Investors in Switzerland: The representative and paying agent of FundLogic Alternatives plc, an Irish UCITS fund, in Switzerland is BNP PARIBAS Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich. The prospectus and the key investor information documents for Switzerland, the articles as well as the annual and semi-annual reports of FundLogic Alternatives plc may be obtained free of charge from the representative in Switzerland

This communication or any portion hereof, may not be reprinted, resold or redistributed without the prior written consent of Morgan Stanley.

Copyright © by Morgan Stanley 2014, all rights reserved.

FOR BUSINESS AND PROFESSIONAL INVESTORS ONLY AND NOT TO BE USED WITH THE GENERAL PUBLIC. Applications for shares in any sub-fund of the FundLogic Alternatives plc (the "Fund") should not be made without first consulting the Fund's current Prospectus, KIID, Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which are available free of charge from Morgan Stanley & Co International plc. This information has been prepared solely for information purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. Please refer to important information at the end of this document.